Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Mezzion Pharma Co Ltd    140410   KR7140410002

MEZZION PHARMA CO LTD

(140410)
  Report  
No quotes available
-- KRW   --.--%
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Mezzion Pharma announces positive results from the Fontan Udenafil Exercise Longitudinal FUEL Trial, in adolescents with single ventricle heart disease who have undergone the Fontan procedure: Mezzion Pharma Co. Ltd.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:11pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Daily -- Mezzion Pharma Co. Ltd. announced that top line data from the Phase 3 FUEL trial, which was designed to evaluate the safety and efficacy of udenafil for the treatment of certain adolescents with congenital single ventricle heart disease (SVHD), had positive results for key parameters. Although Mezzion is restricted in providing specific data results at the present time due to contractual obligation, the Company is looking forward to publication of the full results in a peer reviewed journal and the presentation of the clinical trial data at a major scientific meeting later this year.

The FUEL Trial is a study in 400 male and female adolescents with a single functional ventricle who had previously undergone Fontan surgical palliation. Study participants were drawn from a total of 30 Pediatric Heart Network http://www.pediatricheartnetwork.org/ (PHN) and auxiliary sites throughout the U.S., Canada, and Korea. The PHN is funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

In view of these results from the FUEL trial and the safety data collected about the drug candidate over other clinical studies, Mezzion Pharma intends to submit a New Drug Application to the U.S. Food and Drug Administration to seek approval for the use of udenafil to treat adolescents with SVHD who have undergone Fontan palliation.

In addition to this FUEL trial, Mezzion continues forward in its clinical efforts with the FALD study, also conducted under the auspices of the PHN, which is measuring the ability of udenafil to impact the effects of Fontan Associated Liver Disease.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Heart Disease Daily, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEZZION PHARMA CO LTD

- No features available -

More news
Financials (KRW)
Sales 2019 20,0 B
EBIT 2019 -28,0 B
Net income 2019 -23,0 B
Finance 2019 16,0 B
Yield 2019 -
P/E ratio 2019 -37,6x
P/E ratio 2020 43,4x
EV / Sales2019 43 497x
EV / Sales2020 7 499x
Capitalization 870 B
Chart MEZZION PHARMA CO LTD
Duration : Period :
Mezzion Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 193 000,00  KRW
Last Close Price 101 200,00  KRW
Spread / Highest target 93,7%
Spread / Average Target 90,7%
Spread / Lowest Target 87,7%
EPS Revisions
Managers
NameTitle
Dong-Hyun Park Chief Executive Officer & Director
James L. Yeager Director, Head-Overseas Research & Development
Dong-Hoon Lee Outside Director
Jefferson J. Gregory Director
Jae-Seung Baek Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
MEZZION PHARMA CO LTD740
MERCK KGAA AG4.82%44 173
WUXI APPTEC CO LTD34.46%15 838
KYOWA HAKKO KIRIN CO LTD-10.41%9 103
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD13.93%8 273
JAZZ PHARMACEUTICALS PLC8.77%7 439